Drug Trial Radar · NCT05904886
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
687
Actual
Start
Sep 14, 2023
Primary completion
May 8, 2025
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version 5, following a memo issued by the Sponsor, participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm are recommended to discontinue tiragolumab treatment unless the investigator decides the benefit outweighs the risk. Participants receiving treatment in atezolizumab plus bevacizumab plus placebo arm must discontinue placebo treatment. Participants may continue receiving active treatment(s) per protocol until loss of clinical benefit or unacceptable toxicity, whichever occurs first.
Conditions
- Hepatocellular Carcinoma
Interventions
AtezolizumabDrug
Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle.
BevacizumabDrug
Bevacizumab will be administered by IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle.
TiragolumabDrug
Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
PlaceboOther
Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: From randomization to the first occurrence of disease progression (PD) or death from any cause, whichever occurs first (up to approximately 21 months)
- Overall Survival (OS)Time frame: From randomization to death from any cause (up to approximately 36 months)
Locations
171 sites in 27 countries. Site status is shown where the registry gives one.
Genesis Cancer Center
Hot Springs, Arkansas
UCSF Fresno at Community Cancer Institute
Clovis, California
City of Hope Cancer Center
Duarte, California
University of California San Diego Moores Cancer Center
La Jolla, California
University of Southern California
Los Angeles, California
Stanford Cancer Center
Palo Alto, California
Va Palo Alto Health Care System
Palo Alto, California
UCLA Cancer Center
Santa Monica, California
Hartford Healthcare Cancer Institute at Hartford Hospital
Hartford, Connecticut
MedStar Washington Hosp Center
Washington D.C., District of Columbia
Florida Cancer Specialists - Fort Myers (Broadway)
Fort Myers, Florida
Miami VA Healthcare System
Miami, Florida
Florida Cancer Specialist, North Region
St. Petersburg, Florida
University of Illinois
Chicago, Illinois
Norton Cancer Institute - Audubon
Louisville, Kentucky
Ochsner Cancer Inst.
New Orleans, Louisiana
Mercy Medical Center
Baltimore, Maryland
Henry Ford Health System
Detroit, Michigan
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Minnesota Oncology Hematology Woodbury
Woodbury, Minnesota
Washington Uni School of Medicine
St Louis, Missouri
NYU Langone
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University
New York, New York
Montefiore Medical Center
The Bronx, New York
James J Peters VA Hospital / Mental Illness Research Education and Clinic Center
The Bronx, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Thomas Jefferson Uni
Philadelphia, Pennsylvania
North Texas VA Medical Center
Dallas, Texas
Kelsey Seybold Clnic
Houston, Texas
Virginia Mason Medical Center
Seattle, Washington
Swedish Cancer Inst.
Seattle, Washington
Univ of Wisconsin-Madison
Madison, Wisconsin
Cliniques Universitaires St-Luc
Brussels, Belgium
UZ Antwerpen
Edegem, Belgium
AZ Delta (Campus Rumbeke)
Roeselare, Belgium
Clinicas Oncologicas Integradas - COI
Rio de Janeiro, Brazil
CEDOES - Diagnóstico e Pesquisa
Vitória, Espírito Santo, Brazil
Oncoclínicas do Brasil - BELO HORIZONTE
Belo Horizonte, Minas Gerais, Brazil
Showing 40 of 171 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.